A first-of-its-kind study will use ultrasound and light therapies to investigate targeted treatment of Alzheimer’s disease, ...
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.
SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...
A class of drugs used to treat diabetes has been linked to a 20% lower risk of dementia and Parkinson's disease. | ...
Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...
A new study by scientists at Nottingham Trent University will use non-invasive techniques to investigate the targeted treatment of Alzheimer's disease, dementia and Parkinson's disease ...
New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.
HealthDay on MSN3d
Some Diabetes Meds Could Lower Odds for Dementia, Parkinson'sA specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback